Obstructive sleep apnea syndrome (OSAS) is characterized by episodes of complete (apnea) or partial (hypopnea) upper respiratory tract obstruction and recurring during sleep, frequently with a decrease in blood oxygen saturation (1).
Introduction
Obstructive sleep apnea syndrome (OSAS) is characterized by episodes of complete (apnea) or partial (hypopnea) upper respiratory tract obstruction and recurring during sleep, frequently with a decrease in blood oxygen saturation (1) .
The ratio of men to women is generally 10:1 in sleep centers. This difference in gender was first emphasized by Wynne et al. (2) ; however, evidence suggests that the gap is not as high as previously thought. Schmidt and his friends Norwara et al. found that in a small study group, 1.1% of women and 2.3% of men had an Apnea-Hypopnea Index (AHI) of >10 (3).
There is speculation that progesterone and estrogen released during the pre-menopausal period serve as a protection against OSAS. The fact that a majority of women with OSAS are morbidly obese and are generally in the post-menopausal period adds to this speculation. For example, one study showed that genioglossus muscle activity was higher in pre-menopausal women than in post-menopausal women, with an increase in muscle activity after estrogen and progesterone therapy in post-menopausal women (4, 5) .
In the Wisconsin Sleep Cohort Study (6) , it was found that menopause was a risk factor for OSAS. When age, alcohol consumption, smoking, hypertension, exercise, cardiovascular disease, and physical condition were not taken into account, it was found that post-menopausal women experienced mild OSAS 2.6-times more, with severe OSAS 3.5-times greater, than those in pre-menopausal women. However, there is no official study to date showing a correlation between neuroendocrine hormone changes and OSAS and menopause symptoms. We aimed to study the correlation and specifications of menopause and neuroendocrine hormone changes with OSAS free from risk factors such as aging, comorbid diseases, and depression and to arrange therapies for patients with the disease. hormone tests from all patients were sent for analysis to the Dokuz Eylül University School of Medicine Hospital Central Laboratory. According to the ESS test results, patients with points between 0 and 9 are not considered to be at risk of OSAS, while patients with 10 points and above are. The ESS test consists of eight questions on a scale of 0-24 and is used to measure daytime sleepiness. Ten points and more indicate clinical daytime sleepiness as opposed to a tendency of sleepiness (7) (8) (9) . The validity and reliability research study for use in Turkey was conducted in 1999 by Ağargün et al. (10) (Table 1) .
Methods
Fifteen patients at risk of OSAS were chosen and invited to the Dokuz Eylül Universty School of Medicine Hospital Chest Diseases Polyclinic for evaluation. One patient was rejected. Fourteen patients had their height, weight, and neck circumference measurements taken in different days in a reserved room. The Baster MLC-150 III (Baster; İzmir, Turkey) device was used to take height and weight measurements, and the Star brand tape was used to measure the neck circumference.
One of the 14 patients consented to the detailed research to determine OSAS risk, but rejected the ear, nose, and throat consultation. Upper respiratory tract consultations of 13 patients were done by a doctor on different days in Dokuz Eylül Universty School of Medicine Hospital Ear, Nose and Throat Polyclinic.
The fourteen patients who were at risk of OSAS were hospitalized for one night in the Dokuz Eylül University School of Medicine Hospital Sleep Disorder Center, and their polysomnographic assessments were done via a 32 channel Medcare Embla A 10 PSG (Texas, USA) device. During polysomnographic recording, EEG, EOG, and EMG tests on the sub-mental and tibialis anterior muscles were also performed. C4-A1, C3-A2, O2-A1, and O1-A2 derivations were used for EEG, EOG-L (left), and EOG-R (right) derivations for EOG.
A heat-sensitive cannula was used for nasal air flow during reportorial monitoring, resulting in the detection of apnea and hypopnea in the patients.
Oxygenation was followed up by a finger-mounted pulse oximeter, reading the values in the color spectrum of oxyhemoglobin and measuring the arterial oxygen saturation. Snore follow-up was fulfilled by a microphone planted on the skin at the larynx. EKG recording of heart rate and rhythm were monitored throughout the night. PSD data were assessed and reported by the same attending technician.
Statistical analysis
Statistical Package for Social Sciences for Windows 17.0 (SPSS 17, IBM, Corp.; New York, USA) was used to perform statistical analysis and assessment of data. The chi-square test was used to determine qualitative variables, and the independent T-test was used to determine quantitative variables. Results were evaluated between 95% confidence interval and relevance in p<0.05 level of significance.
Results
The average age of the patients was 55.45±67.1 years. Table 2 shows education levels and occupation and marital statuses of the patients.
One of the 15 patients having more than 10 points on the ESS scale rejected ear, nose, and throat consultation. Another patient rejected ear, nose, and throat consultation and PSG. Table 3 shows the specifications of the 14 patients.
The average total sleep time of the 14 patients who underwent PSG was 398.57±49.75 min. The average sleep efficiency value was 84.57%; the average AHI was 23.90±22.23, and the lowest oxygen saturation average value was 81.64±7.72. Nine patients having CPAP consultation were found to have an average CPAP of 7.16±1.27 mmHg.
When calculating the prevalence of OSAS, the patient who had more than 10 points on the ESS and rejected PSG and ear, nose, and throat consultation was omitted. Of 193 patients, 12 (6.21%) were found to have OSAS. The patients were re-grouped again, separating those with detected OSAS from those were undetected.
The average BMI was found to be statistically higher in the group with OSAS (p<0.026). Patients in the OSAS group were obese as opposed to patients without OSAS, who had normal to above normal weight levels. Patients with BMIs of 0-29.9 kg/m 2 were defined as normal and above normal, while those with BMIs of 30 kg/m 2 and above were defined as obese. It can also be said that having a BMI above 30 kg/m 2 increased the disease risk (relative risk: by 11.16 times).
While the average levels of hormones such as thyroid-stimulating hormone, follicle-stimulating hormone, testosterone, T 3 , dehydroepiandrosterone, sex hormone-binding globulin, and T 4 were not statistically different (p>0.05) between the groups, prolactin, luteinizing hormone (LH), estradiol (E 2 ), and free testosterone average level were statistically different ( Table 4 ).
The average levels of prolactin, LH, and E 2 were found to be higher in the group without OSAS, and the average free testosterone level was found to be higher in the group with OSAS (Table 4) .
Discussion
OSAS is a frequently seen disease in society and causes serious morbidity and mortality. When diagnosing OSAS in pre-menopausal women, male gender is a free risk factor as 85% of sleep studies are conducted on male participants, whereas risk factors for women increase in the post-menopausal period (11-13).
Excluding age, BMI, and lifestyle, respiratory disorders are 2.6-times higher in light sleepers, with more severe forms being 3.5-times more prevalent in post-menopausal women than in premenopausal women (6) . In view of recent data, menopause itself is a free risk factor for sleep-disordered breathing. Bixler et al. (12) contacted 12,219 women by phone, and 1000 were selected for studying PSG. It was found that mild and severe OSAS prevalences in post-menopausal women who did not use HRT were 9.7% and 2.7%, respectively, while for pre-menopausal women, it was 3.2% and 0.6%, respectively (12) . We calculated the percentage of OSAS to be as high 6.21% in our study, with 28.6% of 12 patients having mild OSAS and 57.2% having moderate-severe OSAS.
The primary mechanism behind the increase in the frequency of OSAS during the menopausal period was the difference in the increase of body fat distribution accompanying menopause (13, 14) . There was no significant statistical difference found among meno- pause patients with or without OSAS in terms of average BMIs, despite all patients being of similar age. It can be said that the group with OSAS was obese and that the group without OSAS had normal to above normal weight. However, in their study on post-menopausal and pre-menopausal women, Yukawa et al. (15) found similarities in terms of AHI -that pre-menopausal women had higher BMI. Guilleminault et al. (16) showed that pre-menopausal women with the same degree of obesity had more severe OSAS than postmenopausal women (16) . Therefore, it is not possible to explain the increase in OSAS risk during menopause merely due to obesity.
Another mechanism behind the increasing risk of OSAS during menopause is hormonal changes. It is argued that young women are protected from apnea development by the effect of estrogen on the upper respiratory tract (17) .
When women with severe OSAS are compared to those with or without moderate OSAS within the same age range and menopausal condition, it was found that women with severe OSAS had lower E 2 levels (18). However, there are studies showing that low E 2 concentrations are not as important as high BMI and still face morphology (14, 19) . In accordance with the hypothesis that E 2 protects women from OSAS, we found E 2 levels to be significantly lower in the group with OSAS than in the group without OSAS. However, we think that the reason for the low E 2 levels, despite having a high BMI in the group with OSAS, is that we had a small number of patients in our study, resulting in low reliability when testing the E 2 level.
One of the reasons for the increased frequency of OSAS in postmenopausal women is caused by an increase in testosterone levels (12) . Apart from age, there are clinical studies indicating that hypogonadal men who have testosterone replacement therapy experience developing or deteriorating OSAS symptoms (20) (21) (22) . Testosterone decreases apnea development (23) , and studies have shown that men with low testosterone levels have OSAS (24, 25) . Moreover, young women who have increased androgen levels because of polycystic ovarian syndrome are found to have higher AHIs than the healthy control group (26) . In light of these data, it is still not possible to clearly understand the role of testosterone in respiration.
Different from E2, testosterone is believed to cause sleep disorder by effecting central mechanisms but not the upper respiratory tract (27) . Zhou et al. (23) found that women who had transdermal testosterone replacement therapy developed central apnea during NREM sleep. When patients with OSAS and related symptoms were compared, we concluded that while there was no difference in terms of testosterone levels, free testosterone levels were significantly higher in groups with OSAS. This is contrary to the abovementioned studies that show the increasing effect of testosterone on ventilation; instead, it supports studies that show that it increases OSAS frequency.
In addition, it has been suggested that obese women with OSAS who are free from menopause have higher androgen levels than women who are not obese (28, 29) . This also is compatible in patients with OSAS who are obese and have higher free testosterone levels.
While there are many studies in the literature showing that prolactin and LH secretion is inconsistent in patients with OSAS (20, 30-33), we think that the reason for this difference between the two groups in terms of prolactin and LH levels (prolactin, p=0.036 and LH, p=0.048 ) is insignificant, considering the number of patients who were studied. If the number of patients increases, there is a probability this will also disappear.
Conclusion
We think that an increased OSAS risk during menopause is a health problem related to multi-factorial reasons associated with cardiovascular disease, neurocognitive insufficiency, and daytime sleepiness. Although the disease is frequent and causes serious social problems, unfortunately, there are not enough studies about this condition in Turkey or worldwide. We hope that our study will stimulate future studies on this issue.
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